Table 2.

Multivariate analysis for OS, chemorefractoriness, and fludarabine refractoriness in CLL

HR (95% CI)P
OS*
    Age >65 y4.98 (2.45-10.10)<0.001
    Binet B-C3.01 (1.67-5.42)<0.001
    TP53 mutations3.20 (1.52-6.70)0.002
Time to chemorefractoriness
    TP53 mutations3.97 (2.09-7.51)<0.001
    Lines of treatment >22.55 (1.39-4.66)0.002
    Age >65 y2.27 (1.28-3.85)0.004
    IGHV homology ≥98%1.88 (1.02-3.44)0.041
Time to fludarabine refractoriness
    TP53 mutations6.72 (2.61-17.21)<0.001
  • Abbreviations: 95% CI, 95% confidence interval; P, P value calculated by Cox analysis.

  • * Covariates at CLL diagnosis that entered the analysis were TP53 mutations, IGHV gene homology, del17p13, CD38 expression, age, Binet stage, and levels of LDH and β2-microglobulin.

  • Covariates that entered the analysis were TP53 mutations, IGHV gene homology, del17p13, CD38 expression, age, number of lines of treatment, and fludarabine-based treatment.

  • Covariates that entered the analysis were TP53 mutations, IGHV gene homology, del17p13, CD38 expression, age, and number of lines of treatment.